Merck, a leading science and technology company, has acquired Massachusetts-based Erbi Biosystems, a developer of the 2 ml micro-bioreactor platform technology, known as the “Breez™”. The deal strengthens Merck’s upstream portfolio in therapeutic proteins by enabling scalable cell-based perfusion bioreactor processes from 2ml to 2000L with rapid lab-scale process development. It also offers future development opportunities in novel modality applications, including cell therapies..

Merck, a leading science and technology company, has opened a commercial facility for its new Millipore® CTDMO Services offering at the company’s site in Martillac, France. The 2,700-square-meter facility will provide global supply of commercial drug substances, including mAbs and other recombinant proteins, from an integrated site featuring state-of-the-art single-use equipment and onsite regulatory, quality and technical experts...

Merck, a leading science and technology company, has opened a viral clearance (VC) laboratory as part of the first building phase of its new €29 million China Biologics Testing Center. The 5,000 square meter center is the first of its kind for Merck in China. The VC laboratory allows customers to locally conduct viral clearance studies from pre-clinical development to commercialization and will meet the double-digit demand for VC testing services in China...

Merck, a leading science and technology company, strengthens its manufacturing capabilities for single-use assemblies, a key technology for the production of Covid-19 vaccines and other lifesaving therapies, by investing more than € 130 million in Molsheim, France. The investment is the largest ever in the 50-year history of the site and will create more than 800 jobs by the end of 2028...

Merck, a leading science and technology company, has announced that it has entered a collaboration with Agilent Technologies to advance Process Analytical Technologies (PAT). PAT, which is strongly encouraged by global regulatory authorities, is a key enabler for real-time release and Bioprocessing 4.0. “The biopharmaceutical industry is on a rolling transformation to evolve and digitalize the next generation of bioprocessing to increase accessibility and lower the cost of biologics...

Merck, a leading science and technology company, has signed an agreement with the Administrative Management Committee of Wuxi National High-Tech Industrial Development Zone to significantly expand Merck’s first Asia-Pacific Mobius® Single-Use manufacturing center in China. For more than two decades, Merck’s Life Science business sector...

Merck, a leading science and technology company, is expanding its membrane and filtration manufacturing capabilities in Ireland. The company will invest approximately €440 million to increase membrane manufacturing capacity in Carrigtwohill and to build a new manufacturing facility at Blarney Business Park, both in Cork, Ireland. The investment, which is the largest in a single site ever for Merck’s Life Science business sector, will create more than 370 permanent jobs by the end of 2027...

Merck, a leading science and technology company, has announced its further commitment to Science, Technology, Engineering and Math (STEM) education, with the launch of the 2022 Curiosity Cube® mobile science lab in Europe and North America.. The Curiosity Cube—a retrofitted shipping container that features hands-on science experiments designed to spark student interest in STEM careers—will engage young minds at schools and public spaces...

Merck, a leading science and technology company, announced that its Life Science business sector earned an Accountability, Consistency and Transparency (ACT) label for its ZooMAb® recombinant antibodies platform from My Green Lab, a non-profit organization dedicated to creating a culture of sustainability in science. The first-ever antibody to achieve ACT label designation, ZooMAb®antibodies received the lowest Environmental Impact Factor (EIF) scores in the chemicals and reagents category­...

Merck, a leading science and technology company, will advance its bioprocessing portfolio with the acquisition of the MAST® (Modular Automated Sampling Technology) platform from Lonza. The MAST® platform is an automated, aseptic bioreactor sampling system developed in Bend, Oregon, USA. The financial details of the deal were not disclosed...

Merck, a leading science and technology company, has unveiled a representative study on scientific research productivity. Research productivity is defined in this study as the ratio of measurable input (e.g. number of researchers, financial investment) to measurable output (e.g. patents, publications). The study identified four factors that impact on research productivity in organizations worldwide...

Merck, a leading science and technology company, has announced the winners of this year’s Future Insight Prize. The € 1 million prize in the category of “Food Generation” was awarded during the Future Insight Days in Darmstadt, Germany, to Ting Lu, Professor of Bioengineering at the University of Illinois Urbana-Champaign, USA, and Stephen Techtmann, Associate Professor of Biological Sciences at Michigan Technological University, USA....

While the cultured meat industry is gaining momentum, scaling up the production process and reducing the cost remain key challenges. The primary focus of the collaboration between Merck and the two universities will be the development of next generation, scalable bioreactor designs that can support meat and seafood manufacture on a commercial scale....

To meet the high demand for lipids, a key component of mRNA-based vaccines and therapeutics, Merck, a leading science and technology company, has launched a new, high-purity synthetic cholesterol product, nine months ahead of schedule. “Tapping into two decades’ experience of developing and manufacturing high-quality lipids, we designed a proprietary process to bring our new SAFC® synthetic cholesterol product to market nearly a year early,” said Andrew Bulpin...

Merck, a leading science and technology company, has announced the broadening of its manufacturing footprint with a combined €40 million investment at its production facilities in Danvers, Massachusetts, and Jaffrey, New Hampshire, USA. These sites supply critical products to customers developing lifesaving therapies, including Covid-19 vaccines, as well as provide products and services for biopharmaceutical manufacturing...

Merck announce the launch of its new Scepter™ 3.0 handheld automated cell counter, a solution that enables convenient, on-demand cell volume, cell diameter and cell concentration data. The device uses precision microfluidics to measure and count cells via electrical impedance within 30 seconds. The Scepter™ 3.0 cell counter offers researchers true automation without the risk of error that accompanies vision-based systems, using a combination of analog and digital hardware for sensing, signal processing, data storage, and graphical display....

Merck, a leading science and technology company, has announced a collaboration with Mammoth Biosciences Inc., of South San Francisco, California, USA, for the development, scale-up and commercial production of Mammoth’s CRISPR-based SARS CoV-2 diagnostic test. Mammoth’s high-throughput systems will be compatible with both nasal swab and saliva samples and are targeting approximately 1,500 tests per 8-hour shift with minimal user interaction....

Merck, a leading science and technology company, has announced a € 59 million expansion of its HPAPI and ADC manufacturing capabilities and capacity at its facility near Madison, Wisconsin, USA. This investment will allow large-scale manufacturing of increasingly potent compounds for therapies that have the potential to treat cancer. Completion is expected by mid-2022 and should add approximately 50 full-time jobs starting in 2021...

Merck, a leading science and technology company, opened its M Lab™ Collaboration Center in Shanghai, the company’s largest of nine centers worldwide. “With the booming pharmaceutical industry in Asia and greater emphasis on novel drug therapies, we see an increase in R&D on leading-edge treatments including cell and gene therapies in China,” said Udit Batra, member of the Merck Executive Board and CEO, Life Science....

Merck, a leading science and technology company, has announced plans to build a new, €18 million laboratory facility in Buchs, Switzerland to support the company’s rapidly growing reference materials business. This new laboratory will allow us to continue to drive innovation in diagnostics and testing and expand our research and development of analytical standards...

Merck, a leading science and technology company, has announced that VAR2 Pharmaceuticals has been selected as the European winner of its 2020 Advance Biotech Grant Program. Copenhagen, Denmark-based biotechnology company VAR2 Pharmaceuticals was chosen for its development of a promising novel cancer treatment that has the potential to treat multiple types of human solid tumors....

A new report details potential paths to solutions to overcoming the global Covid-19 crisis and ways to prepare for or even prevent a future pandemic. "There is a tremendous need for a common set of scientific facts about the virus and reliable, verified data," said "Udit Batra, member of the Merck Executive Board and CEO, Life Science. "We are aiming to establish a common baseline of agreed priorities upon which we can engage the wider scientific and innovation community to...

Four leading participants from the problem-solving exercise will provide facts and data-driven insights on their methodology as well as steps forward to accelerate global recovery from Covid-19 and build the infrastructure to combat future public health crises. This live, virtual event will include an audience Q&A. The six-part series is hosted by the Life Science business of Merck....

First solution for simultaneous gene perturbation measurement and unbiased single-cell gene expression. Merck, a leading science and technology company, and 10x Genomics, Inc., a single cell and spatial genomics technologies company, have announced that they have developed a powerful new option for biological experiments. “Researchers today require more detailed information to better understand the relationship between specific genes and disease...

Merck and Baylor College of Medicine have announced an extension of their ongoing collaboration to advance a manufacturing platform to fight Covid-19, designed to accelerate transition to Phase 1 clinical trials. “Vaccine manufacturing is extremely complicated, so we are collaborating on a process development approach to accelerate manufacturing of Baylor’s Covid-19 vaccine candidate...

Conversations on face mask efficacy and supply for frontline workers and the general public have been heated topics amid the Covid-19 pandemic. As the first in a series of monthly “Pandemic Response Catalyst Conversations,” three leading scientific experts will provide facts and data-driven insights on the current global mask supply, filtration properties of masks and a preview of technological innovations improving masks...

Merck, a leading science and technology company, has announced a second Carlsbad, California, U.S.A.-based facility for its BioReliance® viral and gene therapy service offering. The new, € 100 million commercial facility is expected to open next year. “Viral vector manufacturing has transitioned from a niche industry to the cornerstone of the future of biopharmaceuticals,” said Udit Batra, member of the Merck Executive Board and CEO, Life Science....

Merck has unveiled the next component of its BioContinuum™ Platform, the Bio4C™ Software Suite, creating a first-of-its-kind ecosystem that combines process control, analytics and plant-level automation. This transformative software suite will allow users to look across the entire manufacturing process versus individual operational units, giving biomanufacturers complete process control and deep insights...

Merck, a leading science and technology company, and The Jenner Institute today announced that the Jenner Institute has laid the foundation for large-scale production of its Covid-19 vaccine candidate, ChAdOx1 nCoV-19. With patients enrolled for clinical trials for this vaccine, rapid development of the large-scale manufacturing process is a critical step in quickly and safely delivering it from the lab to patients....

Merck has launched its LANEXO™ Lab Inventory, Safety and Compliance Management System, a new digital laboratory informatics solution designed to drastically reduce¹ time in labs and improve data quality and traceability. “Today, 85 percent of labs are using paper or Excel to manage consumables data, and 25 percent of time is spent managing these data — taking scientists away from bench research,” said Jean-Charles Wirth...

Merck, a leading science and technology company, has announced that it has been selected by Swedish molecular diagnostics firm Elypta as the contract manufacturer for Elypta’s clinical diagnostic liquid biopsy kits. The kits analyze metabolites deregulated in several cancer types, making diagnoses more accurate. “Both small and large diagnostic and clinical testing kit manufacturers struggle to find high quality, reliable contract manufacturing organizations like us,” said Jean-Charles Wirth, head of Applied Solutions, Life Science, at Merck....

Merck, a leading science and technology company, has introduced its BrightLab™ cloud-based inventory management and instrument connectivity platform for research scientists. The new software includes an electronic lab notebook, which allows scientists and lab managers to track and update experiments from any computer or mobile device. “In today’s research environment, analog methods of documentation and analysis often take us away from the research itself....

BioMed X has announced the start of a new joint research group in collaboration with Merck. With this new group, BioMed X and Merck extend their ongoing collaboration to a total of six joint research projects at the BioMed X Innovation Center in Heidelberg, Germany. The new project will focus on the role of the intestinal epithelial barrier in the development and exacerbation of autoimmune diseases such as systemic lupus erythematosus (SLE) and multiple sclerosis (MS)....

Merck, a leading science and technology company, has announced that it has signed a license agreement providing Promega Corp., a global life science manufacturer based in Madison, Wisconsin, USA access to Merck’s foundational CRISPR intellectual property. Promega will use Merck’s CRISPR genome-editing technology to create research products and services, including those for drug development.

Merck, a leading science and technology company, today announced that the Japan Patent Office and the Intellectual Property Office of Singapore have each allowed the company’s patent application for the use of paired CRISPR nickases, bringing Merck’s number of patents to 22 worldwide. “Paired nickases represent a significant step in increasing specificity through a highly flexible and efficient approach to reduce off target effects in gene editing,” said Udit Batra....

Merck, a leading science and technology company, has announced that it has signed a license agreement providing Evotec SE access to Merck’s foundational CRISPR intellectual property. Evotec, an international biotechnology company headquartered in Hamburg, Germany, will use Merck’s CRISPR genome-editing technology to create edited cell lines for Evotec’s commercial and internal research purposes....

Merck, a leading science and technology company, has announced an RMB 100 million (€ 13 million) seed fund targeted at startups in China. The company also officially opened its innovation hub in Shanghai and announced plans to officially open a second innovation hub in Guangzhou in November. “Our RMB 100 million China seed fund underlines our commitment to invest in the Chinese market,” said Stefan Oschmann, CEO and Chairman of the Executive Board of Merck....

Merck, a leading science and technology company, has announced that the European, Israeli, South Korean and U.K. intellectual property offices have issued formal notices allowing seven additional Merck patent application claims covering CRISPR gene-editing technology, bringing the number of patents to 20 worldwide....

Merck has acquired BSSN Software, a Darmstadt, Germany-based laboratory informatics company that makes data more readily accessible for ease of integration, collaboration, analysis and long-term archiving. “BSSN Software and the capabilities that it brings will allow Merck’s customers to better use and share their scientific data — the most important part of laboratory experiments,” said Jean-Charles Wirth, head of Applied Solutions at the Life Science business sector of Merck...

Merck, a leading science and technology company, and the Broad Institute of MIT and Harvard (Boston, Massachusetts) have announced an agreement to offer non-exclusive licenses to CRISPR intellectual property (IP) under their respective control for use in commercial research and product development....

Three-year cooperation between both companies. Unique approach to quantum chemistry on near-term quantum computers. Merck, a leading science and technology company, today announced a three-year cooperation with Heisenberg Quantum Simulations (HQS), a startup based in Karlsruhe, Germany. The cooperation between the startup and Merck Digital will focus on applying and commercializing software...

Merck and Rigaku Corp. have signed a joint development agreement to develop lab consumables based on highly innovative crystalline sponge technology. Merck and Rigaku are collaborating to develop commercially available lab solutions employing highly innovative crystalline sponge technology. Merck will develop lab consumables to determine the absolute chemical structure of substances on sub-microgram scale.....

Merck, a leading science and technology company, today announced the winners of its Advance Biotech Grant program in North America during its Biotech Start-up Summit at the Cambridge Innovation Center (Massachusetts, U.S.). The grant is given to small- and mid-size biotechnology companies that need funding and expertise to get their therapies to market. “With more than 60 percent of drugs in the pipeline today...

Merck, a leading science and technology company, has announced that it has opened the next round of applications for startup companies to participate in the global Merck Accelerator program. Startups can choose to participate in one of the two programs, either at the company’s Innovation Center at global headquarters in Darmstadt or at its China Innovation Hub in Shanghai.

Merck, a leading science and technology company, announce its participation in a collaboration with the Vaccine Formulation Institute and the European Vaccine Initiative. The effort will provide vaccine process development training courses within TRANSVAC2, a collaborative infrastructure project under Horizon 2020. “Involvement in this project is a natural extension to our longtime focus on accelerating vaccine....

Merck, a leading science and technology company, has announced that Susumu Kitagawa, Professor at the Institute for Integrated Cell–Material Sciences at Kyoto University, Japan, has been named the sixteenth recipient of the Emanuel Merck Lectureship. He is being recognized for his pioneering scientific work in the field of metal organic frameworks (MOFs). His fundamental contributions to the development of this innovative class of nanoporous materials could lead to new ways...

Merck, a leading science and technology company, has announced that it has entered into an agreement with HistoCyte Laboratories Ltd, Tyne, U.K., to be the exclusive multinational distributor of the company’s portfolio of cell line reference products for immunohistochemistry and in situ hybridization....

Merck, a leading science and technology company, has launched the new Stericup^® Quick Release 500 ml vacuum filtration system, a filter bottle system ideally suited for sterile filtration of cell culture media, buffers and reagents.

The Stericup^® Quick Release system is the next generation of the original Stericup^® Sterile Vacuum Filtration System, which has been a staple in labs around the world for decades. The improved liquid sterile filtration system offers ergonomic design updates that optimize user control and...

Merck’s ReadyPlate™ 55 ready-to-use agar plates offer streamlined, convenient and efficient sample testing for quality control of water and filterable beverages.

With a diameter of just 55 mm, ReadyPlate™ 55 plates are much smaller than standard 90 mm plates, freeing up valuable space in the incubator while reducing waste. The plates are available in a variety of certified kits which combine the agar plates with matching membranes needed for testing....

Merck's Advanced Proteomics Grade SOLu-Trypsin is an exclusive, solution stable enzyme for mass spectrometry.

Designed to be stable in solution when refrigerated, SOLu-Trypsin can be used immediately without preparation. Other forms of trypsin require thawing or reconstitution and must be discarded if not used immediately. SOLu-Trypsin allows excess product to be saved for future use, thus eliminating unnecessary waste and cost.....

Merck, a leading science and technology company, has developed a new genome editing tool that makes CRISPR more efficient, flexible and specific, giving researchers more experimental options and faster results that can accelerate drug development and access to new therapies.

This new technique, called "proxy-CRISPR," provides access to previously unreachable areas of the genome. Most natural CRISPR systems, found in bacteria, cannot work in human cells without significant re-engineering....

Merck has announced that BioInvent International AB, a Swedish company which develops novel immuno-regulatory antibodies to treat cancer, is upgrading and expanding its drug manufacturing facility with a full line of Merck’s Mobius^® single-use bioreactors.

BioInvent will add 3-, 50-, 200- and 1000-liter bioreactors to its upstream facility in Lund, Sweden, expanding capacity and improving flexibility and scalability....

Merck, a leading science and technology company, has announced the global launch of the Milli-Q^® IQ 7000 system, the seventh-generation Milli-Q^® water purification innovation.

This launch marks 50 years of providing ultrapure water to scientists in laboratories all over the world. The company announced details about the water purification system during a press briefing at the Pittcon Conference & Expo 2017 in Chicago, Illinois.

Merck's new Integritest® 5 instrument is an easy-to-use, portable and fully automated integrity test system for verification of filters and processing equipment.

The latest model of the first commercially available automated integrity test instrument introduced more than 25 years ago now incorporates an improved algorithm to simplify test creation and accelerate test completion. The user-friendly software makes it easy to set up and manage users and tests, while offering a depth of advanced functionality for those who need additional options....

Merck, a leading science and technology company, today announced the introduction of its new testosterone calibrator kit for in vitro diagnostic (IVD) use.

The certified kit allows users to calibrate assays and verify calibrations, and is the first of its kind to receive CE mark approval, indicating compliance with the European Union's Medical Device Directive. The CE mark allows the kit to be marketed and sold in the European Union and in any country recognizing CE mark approval....

Product offers smaller sample volumes and four times higher throughput than traditional assays

Merck, a leading science and technology company, today launched the MILLIPLEX^® MAP Human High Sensitivity cytokine panelfor faster and more cost-effective human cytokine assays. The new panel allows researchers to achieve four times higher throughput than traditional assays while using smaller sample sizes....

Merck, a leading science and technology company, has announced that it has entered into a set of agreements with Evotec AG, whereby Evotec AG will provide screening services for Merck's collection of genetic reagents such as CRISPR and shRNA libraries.

Merck, a leading science and technology company, has launched the CellASIC® ONIX2 Microfluidic System for advanced live cell imaging.

The system converts laboratory microscopes into powerful tools for live cell imaging to more effectively perform in-depth analysis of cellular mechanisms and behavior in a live environment....

Merck, a leading science and technology company, today announced that its digital acquisition marketing team won the 2016 US Search award for "Best In-House" team.

New EZ-Fit™ Filtration Units from Merck

Merck has expanded its portfolio of EZ-Fit™ filtration units, ready-to-use, disposable filtration devices for bioburden testing. The new EZ-Fit™ filtration units come with a wide range of membrane sizes to suit all applications, and a new patented drain design to accelerate processing of turbid and hard-to-filter matrices....

Elix^® High-Throughput water purification system delivers up to 9000 liters of pure water daily with real-time monitoring 

Purification technologies ensure constant water quality with low and predictable running costs. Merck, a leading science and technology company, have introduced the Elix^® High-Throughput water purification system, providing laboratories with a reliable water purification solution for daily water volumes of up to 9000 liters...

Merck has entered into an agreement with PCAS S.A. to expand Merck’s excipients portfolio. Under the agreement, Merck will be the exclusive, global distributor of the Expansorb^® line of biocompatible and biodegradable polymers.

The portfolio will include 38 polymers for sustained release of small molecule and selected peptide injectables, allowing customers to optimize and precisely control release kinetics of final drug products. The ability to better control and sustain the release of drugs allows for delivery via reduced numbers of injections with the same therapeutic efficacy...

Emprove^® risk assessment program provides easy access to information on materials used for drug product manufacturing

Merck has expanded its industry-leading Emprove^® risk assessment program to include a selection of products for filtration and single-use processing. The program provides documentation and regulatory information on materials used in the manufacture of drug products.....

Program aims to improve access to cancer care in Africa and increase number of oncologists on the continent - Paediatric and adult medical fellowship planned for African doctors in India

Merck, a leading science and technology company, today announced to start the first Merck Africa Medical Oncology Fellowship Program for Sub-Saharan African countries in partnership with University of Nairobi, Kenya. The program will be conducted at University of Nairobi and is part of Merck’s efforts to improve access to cancer care and strengthen the healthcare system in emerging markets....

Merck, a leading science and technology company, is expanding its popular line of Guava® flow cytometers to include a high-power modulated green laser. 

The addition of a 532 nanometer laser expands the detection capabilities of the Guava® easyCyte instrument line to enable simultaneous detection of multiple fluorescent proteins. It also offers researchers more spectral choice using fluorescent reagents. More powerful violet, blue and red lasers are now standard in most configurations, meaning the Guava® cytometers are sensitive enough to detect subcellular particles as small as viruses....

Merck, a leading science and technology company, today introduced the IsoBag™ for faster, easier and more convenient transfer of contact and settle plates to production isolators. 

The new IsoBag™ offers a more streamlined alternative for environmental monitoring, and helps make workflows more efficient, productive and flexible. In traditional environmental monitoring workflows, single-bagged plates are decontaminated and stored in the isolator. Limited space in the isolator allows storage of only a small supply of ready-to-use plates. When this supply runs out, workflows are interrupted for...

Merck, a leading science and technology company, reported record results for 2015, emerging stronger from the transformation process that started in 2007. Net sales and EBITDA pre exceptionals were higher than ever before in Merck’s history of nearly 350 years.

“2015 was not only an eventful, but above all a very successful year for Merck. We again achieved profitable growth. By acquiring Sigma-Aldrich, we successfully completed the portfolio realignment of recent years. In immuno-oncology, we initiated six pivotal clinical trials. Research advances and future-oriented investments form the foundation for future success. And our new bold and vibrant branding shows what makes Merck unique,” said Karl-Ludwig Kley, Chairman of the Executive Board....

Merck, a leading science and technology company launch a range of new products for separation and analysis

The innovations include high performance liquid chromatography (HPLC) and capillary gas chromatography (GC) columns, and tools for effective analysis of water and easier sample preparation. "We are committed to providing innovations that help our customers solve their toughest problems, advance science and accelerate access to health care around the world," said Udit Batra, CEO of Merck's life science business

Merck Millipore's heipha ICRplus Neutralizer A contact plates improve detection of microorganisms on disinfected surfaces in isolators and cleanrooms.

Common disinfectants may contain residues from a variety of sources that inhibit the detection of microorganisms during surface monitoring, which can lead to false negative results. Heipha Neutralizer A ICRplus contact plates allow the detection of microorganisms in the presence of many disinfectants, including those which cannot be sufficiently inactivated by common neutralizers, such as polysorbate 80, lecithin, histidine and thiosulfate...

Merck Millipore, the Life Science division of Merck, has introduced the SNAP i.d.® 2.0 Protein Detection System for Immunohistochemistry (IHC), which streamlines immunohistochemistry workflows and significantly decreases slide handling time.

The system enables parallel processing of up to 24 tissue slides at a time, making it easier to apply consistent conditions and reduce potential process variability inherent in manual IHC methods. The system's intuitive format reduces slide handling and speeds wash steps during blocking, washing, antibody incubation and labeling. A controlled vacuum force removes solutions evenly from all slides at once, in seconds. This approach systemizes the handling of...

Merck Millipore, the Life Science division of Merck, has launched the EZ-Fit™ Filtration Unit, a ready-to-use, disposable filtration device for bioburden testing.

The system is faster and more efficient than traditional methods, resulting in increased reliability and streamlined workflows. The unit, which conforms to international standards (EP/USP) and water testing regulations, can be used for filtration of liquid samples including water, raw materials, in-process samples and final products. "The EZ-Fit™ Filtration Unit represents the latest addition to our comprehensive portfolio of products that facilitate and...

Polyplus-transfection SA, a privately-held company developing innovative technologies for molecular and cellular biology and Merck, a leading pharmaceutical, chemical and life science company with total revenues of EUR 11.2 billion in 2012, announce today a global prior use license agreement and extended supply agreement for Polyplus-transfection’s polyethylenimine (PEI) based transfection reagents. Financial details were not disclosed.

Polyplus-transfection has granted Merck rights to the prior use of PEI for transfection. Polyplus-transfection will also supply Merck sites worldwide with batches of high quality linear PEI transfection reagent. The reagent is specifically formulated and subject to appropriate quality controls (transfection activity and microbiological tests). These ensure reliable, safe and reproducible protein production in medium to large scale....